ReviewProceedings (Baylor University. Medical Center)2025
Should transjugular intrahepatic portosystemic shunt be first-line therapy for preventing esophageal variceal rebleeding? A meta-analysis of clinical outcomes.
Review in Proceedings (Baylor University. Medical Center), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: According to Baveno VII guidelines, endoscopic band ligation (EBL) plus nonselective beta-blockers (NSBB) is first-line therapy for preventing esophageal variceal rebleeding, with transjugular intrahepatic portosystemic shunt (TIPS) being used in cases of treatment failure. Our study aimed to compare TIPS with EBL plus NSBB in terms of overall mortality and rate of variceal rebleeding. Methods: We conducted a comprehensive search on Medline, Google Scholar, Embase, and the Cochrane Library up to January 25, 2025. Randomized control trials (RCTs) comparing TIPS with EBL plus NSBB for variceal bleeding were included in the study. Results: Eight RCTs with 629 patients, 336 receiving TIPS and 293 receiving EBL + NSBB, were included. TIPS had significantly lower rates of variceal rebleeding (odds ratio 0.30, 95% confidence interval 0.19-0.49, Conclusion: TIPS offers significant advantages over EBL plus NSBB in reducing variceal rebleeding and other complications but does not improve mortality. Further high-powered trials are needed to refine management strategies for variceal rebleeding in cirrhotic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.